Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rahul Sharma

Interventional Cardiology Stanford, CA Medical Doctor

NPI 1548735509 CMS profile 5695158

300 Pasteur Dr, Stanford, CA 94305

Open in the dashboard

General payments

$1,033,088

1,800 records reported · program years 2019–2025

Research payments

$4,950

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,551,674 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Rahul Sharma of Stanford, CA is reported in the CMS Open Payments database as having received $1,033,088 across 1,800 general payments and $4,950 in research payments paid to them. Separately, studies naming them as principal investigator received $5,551,674 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $138,515 281
2024 General $170,277 328
2024 Research $4,950 1
2023 General $324,972 320
2022 General $68,534 271
2021 General $118,941 231
2020 General $123,264 158
2019 General $88,585 211

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rahul Sharma
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Rahul Sharma were reported at $138,515. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Rahul Sharma Interventional Cardiology median Middle half National median
2019 $88,585 $1,097 $329–$3,048 $163
2020 $123,264 $473 $161–$1,480 $114
2021 $118,941 $677 $233–$1,827 $132
2022 $68,534 $978 $333–$2,724 $149
2023 $324,972 $1,136 $382–$2,986 $160
2024 $170,277 $1,181 $395–$3,326 $164
2025 $138,515 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $515,851 1,158 payments
  2. CathWorks, Inc. $257,239 51 payments
  3. Abbott Laboratories $102,826 196 payments
  4. Siemens Medical Solutions USA, Inc. $44,456 21 payments
  5. Shockwave Medical, Inc $40,174 74 payments
  6. Medtronic, Inc. $18,276 73 payments
  7. Philips Electronics North America Corporation $18,092 55 payments
  8. Cardiva Medical, Inc. $14,769 13 payments
  9. Boston Scientific Corporation $8,954 107 payments
  10. Opsens Inc. $8,041 7 payments
  11. Other $4,409 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $604,574 134 payments
  2. Travel and Lodging $187,312 320 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $108,308 25 payments
  4. Food and Beverage $76,569 1,303 payments
  5. Honoraria $29,275 7 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $24,400 8 payments
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,500 1 payment
  8. Entertainment $150 1 payment
  9. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. FFRangio $226,307 45 payments
  2. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $135,903 103 payments
  3. Edwards SAPIEN 3 Transcatheter Heart Valve $117,441 92 payments
  4. PASCAL $59,801 89 payments
  5. AMPLATZER AMULET $45,278 80 payments
  6. ACUSON SC2000 Diagnostic Ultrasound System $43,839 18 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $33,756 63 payments
  8. FFRangio System $30,932 6 payments
  9. JETI ALL IN ONE NON-STERILE KIT $19,950 9 payments
  10. Mitra Clip system $17,054 18 payments
  11. Other $134,816 917 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $4,950 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

39

Median for Cardiology: 2,533

Drug cost

$448

Median for Cardiology: $485,213

Branded share of claims

56.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 22 $392
Prednisone Generic 17 $56

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$223,699

Medicare's payments for the services billed

Medicare patients

428

Average age 77

Services billed

757

212 women, 216 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 67%
Atrial fibrillation 64%
Chronic kidney disease 62%
Arthritis 43%
Diabetes 39%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1,801 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record